finnCap - Avacta, Initiation of coverage

Thu, 20 Oct 2016, 08:41am BST

finnCap initiate coverage on Avacta, the preclinical stage biopharmaceutical company. finnCap initiate with a 12-month target price of 200p, implying an EV of c£125m/$150m, which they expect to be reached as the company meets its key identified technical preclinical and commercial milestones.

Mark Brewer
Research Director Life Sciences